Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chlorin e6 heptamethine cyanine conjugate
- Development stage
- Preclinical
- Lead developer
- Cedars-Sinai
- Modality
- Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
A theranostic agent consisting of a conjugate between the photosensitizer chlorin e6 (Ce6) and a heptamethine cyanine dye (such as MHI-148 or IR-783). This conjugate is designed to improve the tumor specificity of Ce6 by utilizing the affinity of heptamethine cyanine dyes for cancer cells, which is mediated by the overexpression of organic anion-transporting polypeptides (OATPs) and hypoxia-induced factors. The agent functions as a multifunctional tool for near-infrared fluorescence (NIRF) imaging, PET imaging (when radiolabeled with 64Cu), and photodynamic therapy (PDT), where it generates cytotoxic reactive oxygen species upon light activation to induce tumor cell death.
- Other names
- photosensitizer-carrier-conjugateCe6-heptamethine cyanine conjugateCe-6-heptamethine cyanine conjugateCe 6-heptamethine cyanine conjugate
02
Targets
HIF3A (Hypoxia-inducible factor 3-alpha)OATP (Organic anion transporting polypeptides)
Beyond the preview
Go deeper on chlorin e6 heptamethine cyanine conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chlorin e6 heptamethine cyanine conjugate.